Amarin | AMRN - Current Assets

Stock Price
15.34
Daily Change
-1.03 -6.29%
Monthly
-1.92%
Yearly
85.36%
Q1 Forecast
14.88

Amarin reported $628.33M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 628.33M 21.52M Sep/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioCryst Pharmaceuticals USD 355.68M 42.78M Sep/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 28.2B 2.26B Sep/2025